Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 37
Encontrada(s) 1 página(s)

e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

Extrapolation of lung pharmacokinetics of antitubercular drugs from preclinical species to humans using PBPK modelling

  • Karakitsios, Evangelos
  • Dokoumetzidis, Aristides
A correction has been published: Journal of Antimicrobial Chemotherapy, Volume 79, Issue 9, September 2024, Page 2411, https://doi.org/10.1093/jac/dkae251, Objectives: To develop physiologically based pharmacokinetic (PBPK) models for widely used anti-TB drugs, namely rifampicin, pyrazinamide, isoniazid, ethambutol and moxifloxacin lung pharmacokinetics (PK)—regarding both healthy and TB-infected tissue (cellular lesion and caseum)—in preclinical species and to extrapolate to humans. Methods: Empirical models were used for the plasma PK of each species, which were connected to multicompartment permeability-limited lung models within a middle-out PBPK approach with an appropriate physiological parameterization that was scalable across species. Lung’s extracellular water (EW) was assumed to be the linking component between healthy and infected tissue, while passive diffusion was assumed for the drug transferring between cellular lesion and caseum. Results: In rabbits, optimized unbound fractions in intracellular water of rifampicin, moxifloxacin and ethambutol were 0.015, 0.056 and 0.08, respectively, while the optimized unbound fractions in EW of pyrazinamide and isoniazid in mice were 0.25 and 0.17, respectively. In humans, all mean extrapolated daily AUC and Cmax values of various lung regions were within 2-fold of the observed ones. Unbound concentrations in the caseum were lower than unbound plasma concentrations for both rifampicin and moxifloxacin. For rifampicin, unbound concentrations in cellular rim are slightly lower, while for moxifloxacin they are significantly higher than unbound plasma concentrations. Conclusions: The developed PBPK approach was able to extrapolate lung PK from preclinical species to humans and to predict unbound concentrations in the various TB-infected regions, unlike empirical lung models. We found that plasma free drug PK is not always a good surrogate for TB-infected tissue unbound PK., This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement no. 853989. The JU receives support from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA and Global Alliance for TB Drug Development Non-Profit Organisation, Bill & Melinda Gates Foundation, University of Dundee. Open access funding provided by HEAL-Link Greece.
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Estudio, informe, memoria (Report)

The ribosomal RNA synthesis ratio biomarker in Mycobacterium ulcerans for drug activity evaluation

  • Calvet Seral, Juan
  • Sáez López, Emma
  • López Expósito, Patricio Roberto
  • Ferrer Bazaga, Santiago
  • Vaquero López, Juan José
  • Ramón García, Santiago
  • Mendoza Losana, Alfonso
Buruli ulcer (BU), a neglected tropical disease caused by Mycobacterium ulcerans (Mul), is treated with an 8-week regimen of rifampicin (RIF) and clarithromycin (CLA). Clinical trials are currently evaluating amoxicillin/clavulanate (AMX/CLV) co-administration to reduce treatment duration. However, conventional methods for assessing in vitro drug efficacy against Mul, like colony-forming units (CFUs), are slow and cumbersome. The ribosomal RNA synthesis ratio (RS-ratio) measures ribosome biogenesis and serves as a proxy of metabolic activity. While it is a promising predictive biomarker for treatment shortening in tuberculosis, its application in Mul remains unexplored. Here, we evaluated the RS-ratio for Mul drug activity assessment through RNA extractions from time-kill assays using RIF, CLA, and AMX/CLV, alone or in combinations. RIF + AMX/CLV-containing combinations produced a potent, rapid RS-ratio reduction, decreasing from a baseline of ≈2000 to ≈200 as early as day 3, and reaching their maximal inhibition (≈50–60) between days 7 and 10. Notably, this metabolic decline preceded the CFUs and luminescence drops observed in prior studies. Interestingly, the RS-ratio detected a metabolic recovery between days 14 and 28 (≈400), suggesting remaining bacterial viability, a phenomenon not observed by CFUs or luminescence. In summary, this is the first report using the RS-ratio to evaluate antibiotic activity against Mul. Our findings validate the RS-ratio as a molecular tool for assessing the sterilizing potential of new regimens to inform future research and clinical trial designs for the treatment of BU. Our results support the RIF + CLA + AMX/CLV regimen selection for BU treatment shortening in the BLMs4BU clinical trials (NCT05169554, PACTR202209521256638)., Innovative Medicines Initiatives 2 Joint Undertaking (JU) (Grant 853989, https://era4tb.org/) to JJV, supported by the European Union’s Horizon 2020 Research and Innovation Program and EFPIA, and the Global Alliance for TB Drug Development Non-Profit Organization, Bill & Melinda Gates Foundation, University of Dundee. (http://www.imi.europa.eu); and the Tres Cantos Open Lab Foundation (Grant TC281) to SRG.
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

Evaluation of critical parameters in the hollow-fibre system for tuberculosis: A case study of moxifloxacin

  • Aguilar-Ayala, Diana Angélica
  • Sanz-García, Fernando
  • Rabodoarivelo, Marie Sylvianne
  • Susanto, Budi O.
  • Bailo, Rebeca
  • Eveque-Mourroux, Maxime R.
  • Willand, Nicolas
  • Simonsson, Ulrika S. H.
  • Ramón-García, Santiago
  • Lucía, Ainhoa
Aims The hollow-fibre system for tuberculosis (HFS-TB) is a preclinical model qualified by the European Medicines Agency to underpin the anti-TB drug development process. It can mimic in vivo pharmacokinetic (PK)–pharmacodynamic (PD) attributes of selected antimicrobials, which could feed into in silico models to inform the design of clinical trials. However, historical data and published protocols are insufficient and omit key information to allow experiments to be reproducible. Therefore, in this work, we aim to optimize and standardize various HFS-TB operational procedures. Methods First, we characterized bacterial growth dynamics with different types of hollow-fibre cartridges, Mycobacterium tuberculosis strains and media. Second, we mimicked a moxifloxacin PK profile within hollow-fibre cartridges, in order to check drug–fibres compatibility. Lastly, we mimicked the moxifloxacin total plasma PK profile in human after once daily oral dose of 400 mg to assess PK–PD after different sampling methods, strains, cartridge size and bacterial adaptation periods before drug infusion into the system. Results We found that final bacterial load inside the HFS-TB was contingent on the studied variables. Besides, we demonstrated that drug–fibres compatibility tests are critical preliminary HFS-TB assays, which need to be properly reported. Lastly, we uncovered that the sampling method and bacterial adaptation period before drug infusion significantly impact actual experimental conclusions. Conclusion Our data contribute to the necessary standardization of HFS-TB experiments, draw attention to multiple aspects of this preclinical model that should be considered when reporting novel results and warn about critical parameters in the HFS-TB currently overlooked., This work has received support from the Government of Aragon, Spain (Ref. LMP132_18; Gobierno de Aragón y Fondos Feder de la Unión Europea ‘Construyendo Europa desde Aragón’) to S.R.G. and from the Innovative Medicines Initiatives 2 Joint Undertaking (grant No 853989) to N.W., U.S.H.S. and S.R.G. The JU receives support from the European Union's Horizon 2020 Research and Innovation Programme and EFPIA and Global Alliance for TB Drug Development Non-Profit Organization, Bill & Melinda Gates Foundation, University of Dundee.
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

Scintillator Geometrical Considerations for Detectors Based on Hexagonal SiPMs

  • Pérez Benito, David
  • Chil, R.
  • Hidalgo Torres, L. A.
  • Vaquero López, Juan José
A truncated icosahedron system with hexagonal detectors has been previously proposed as an approach to the ideal spherical PET scanner. In this work, we explore by Monte Carlo simulations, the role of hexagonal scintillator crystals in terms of light yield, scintillation pulse decay time and energy resolution by comparison with three geometries: square and triangular prisms and cylinder. The relevance of the reflector type (diffuse and specular) and finish (polished and rough) of the scintillation borders was also considered. The light yield for the hexagon is higher by approximately 2% and 4% depending on the finish and reflector type in comparison to the square. The energy resolution is between 0.2% and 1% better for the hexagon. Polished walls with specular reflector have the finest energy resolution. The difference in the pulse decay time among geometries is not determining. The light yield and energy resolution were validated experimentally for rough walls and diffuse reflector. A hexagonal scintillation array of 181 crystals of 1.25 mm of edge was finally manufactured. The flood field image read with four multiplexing channels is presented. The detector offers an excellent crystal identification with a mean peak-to-valley ratio over 13 and an energy resolution of 11.5%., This work was supported in part by the Minister of Science and Innovation of Spain under Grant PDC2021-121788-I00, and in part by the Innovative Medicines Initiative 2 Joint Undertaking (JU) under Grant 853989. The JU receives support from the European Union's Horizon 2020 Research and Innovation Programme and EFPIA and Global Alliance for TB Drug Development NonProfit Organisation, Bill & Melinda Gates Foundation, University of Dundee
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

A systematic review of economic evaluations of pharmacological treatments for active tuberculosis

  • Nagar, Sarosh
  • Nicholls, David
  • Dawoud, Dalia
The continuing spread of tuberculosis (TB) worldwide, especially drug-resistant TB, poses a major challenge to healthcare systems globally. Addressing this requires appraising the cost effectiveness of existing pharmacological interventions against TB to identify key drivers of cost effectiveness and value and guide pharmaceutical innovation and novel drug regimen development. Studies were identified from a search of six database: MEDLINE MEDLINE-In Process, MEDLINE Epub Ahead of Print, EMBASE, Cochrane Database of Systematic Reviews, and Econlit in July 2022. Two reviewers independently assessed all identified studies and reports using pre-defined inclusion/exclusion criteria. Study methodological quality was assessed, data were extracted in standard tables, and results were narratively synthesized. Overall, 991 studies and 53 HTA reports were identified with 20 studies and 3 HTA reports meeting the inclusion criteria. Quality assessment of the 20 studies identified 4 with minor limitations, while the remainder were assessed as having potentially or very serious limitations. Sixteen studies conducted cost-utility analyses, 6 conducted cost-effectiveness analyses, and 2 conducted cost-comparison analyses with some studies performing multiple analyses. The majority (n = 16) were model-based. Eleven studies analyzed the cost-effectiveness of bedaquiline, 6 compared shorter to longer/standard duration regimens, 2 assessed ethambutol, and 1 assessed delamanid. Key drivers of cost effectiveness were drug costs, the number of TB cases, the portion of cases with sputum culture conversion, treatment delivery costs, and treatment efficacy. Common value elements considered included adverse events, drug resistance, and improving treatment adherence. Our results suggest that out of the pharmacological treatments assessed, bedaquiline is likely a cost-effective addition to existing treatment regimens/background treatment regimens, while ethambutol is not likely to be. Newer shorter regimens, even if more costly, seem to be more cost-effective compared to longer regimens. These results illustrate the limited number of novel cost-effective pharmacological interventions and highlight a need to develop new drugs/regimens against TB to overcome resistance, taking into account the key drivers of cost effectiveness and other value attributes identified from this review., This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853989. The JU receives support from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA and Global Alliance for TB Drug Development Non-Profit Organisation, Bill & Melinda Gates Foundation, University of Dundee.
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

Academia and industry agreement on a feasibility tool for first-time-in-human clinical trial units

  • Moraga, Paloma
  • Prieto, Paula
  • Conradie, Almari
  • Benhayoun, Majda
  • Rousell, Vicki
  • Davy, Maria
  • Fuhr, Uwe
  • Antonijoan Arbos, Rosa
  • Abad Santos, Francisco
  • Portolés, Antonio
  • Van Duinen, Jolanda
  • Carcas, Antonio J.
  • Borobia, Alberto M.
First-time-in-human (FTIH) trials are designed to generate information on the safety, tolerability, as well as the pharmacokinetic and pharmacodynamics profile of new drugs. To ensure the safety of participants, these trials need to be conducted at specifically equipped phase I clinical trial units (CTUs). In accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guideline for Good Clinical Practice (GCP) and the European Union (EU) regulatory guidelines, one of the aims of the European Regime Accelerator for Tuberculosis (ERA4TB) project is to collaboratively create a feasibility tool, through a partnership between public and private entities, for the validation of CTUs selected to conduct FTIH trials. A feasibility form, encompassing nine sections, was created to gather information on the unit in relation to key attributes of FTIH trials. Collaboratively, industry and academic partners defined the minimal criteria to ensure the adherence of CTUs to the principles of ICH GCP and regulations outlined by the European Medicines Agency (EMA) for the execution of FTIH trials. Subsequently, all CTUs available for the project were assessed for FTIH trial eligibility. The introduction of the certification procedure through the feasibility tool within ERA4TB resulted in the accreditation of the five academic CTUs, which are now prepared to carry out FTIH trials as part of the Consortium. The developed feasibility tool aims to establish open and widely used minimum requirements for the validation of academic CTUs as FTIH units, marking it as the inaugural tool for CTU validation resulting from the collaboration between industry and academia within the ERA4TB project. The established partnership has enabled an innovative and novel way of working., The project leading to this publication has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 853989. The JU receives support from the European Union's Horizon 2020 Research and Innovation Programme and EFPIA and Global Alliance for TB Drug Development Non-Profit Organization, the Bill & Melinda Gates Foundation, and the University of Dundee.
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

Uptake‐independent killing of macrophages by extracellular Mycobacterium tuberculosis aggregates

  • Toniolo, Chiara
  • Dhar, Neeraj
  • McKinney, John D
Mycobacterium tuberculosis (Mtb) infection is initiated by inhalation of bacteria into lung alveoli, where they are phagocytosed by resident macrophages. Intracellular Mtb replication induces the death of the infected macrophages and the release of bacterial aggregates. Here, we show that these aggregates can evade phagocytosis by killing macrophages in a contact‐dependent but uptake‐independent manner. We use time‐lapse fluorescence microscopy to show that contact with extracellular Mtb aggregates triggers macrophage plasma membrane perturbation, cytosolic calcium accumulation, and pyroptotic cell death. These effects depend on the Mtb ESX‐1 secretion system, however, this system alone cannot induce calcium accumulation and macrophage death in the absence of the Mtb surface‐exposed lipid phthiocerol dimycocerosate. Unexpectedly, we found that blocking ESX‐1‐mediated secretion of the EsxA/EsxB virulence factors does not eliminate the uptake‐independent killing of macrophages and that the 50‐kDa isoform of the ESX‐1‐secreted protein EspB can mediate killing in the absence of EsxA/EsxB secretion. Treatment with an ESX‐1 inhibitor reduces uptake‐independent killing of macrophages by Mtb aggregates, suggesting that novel therapies targeting this anti‐phagocytic mechanism could prevent the propagation of extracellular bacteria within the lung., This work was supported by grants to J.D.M. from the Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF) (310030B_176397). This work has received support from the Innovative Medicines Initiatives 2 Joint Undertaking grant No 853989 “ERA4TB” (https://era4tb.org/). C.T. was supported by funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska‐Curie grant agreement No. 665667. VIDO receives operational funding from the Government of Saskatchewan through Innovation Saskatchewan and the Ministry of Agriculture and from the Canada Foundation for Innovation through the Major Science Initiatives for its CL3 facility.
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

The contribution of microfluidics to the fight against tuberculosis

  • Cañadas Ortega, Marina
  • Gómez Cruz, Clara
  • Vaquero López, Juan José
  • Muñoz Barrutia, María Arrate
The high mortality associated with tuberculosis brings forward the urgency of developing new therapies and strategies against the disease. With the advance of drug-resistant strains, traditional techniques have proven insufficient to manage the disease appropriately. Microfluidic devices have characteristics that can enhance treatment prescription and significantly advance our knowledge about the disease and its interaction within the human body. In addition, microfluidic systems provide advantages in terms of time and costs, which are particularly important in countries with low income and resources. This review will highlight how microdevices can help bridge the gaps in disease management, including their use for drug testing and development, drug susceptibility, basic research, and novel approaches to anti-TB vaccines and organ-on-chip studies., This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 853989. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and Global Alliance for TB Drug Development non-profit organisation, Bill & Melinda Gates Foundation and University of Dundee. This work was partially funded by Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación, under grant PID2019-109820RB-I00, MCIN/AEI/10.13039/501100011033/, co-finance by European Regional Development Fund (ERDF), "A way of making Europe"
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

Microfluidic dose–response platform to track the dynamics of drug response in single mycobacterial cells

  • Mistretta, Maxime
  • Gangneux, Nicolas
  • Manina, Giulia
Preclinical analysis of drug efficacy is critical for drug development. However, conventional bulk-cell assays statically assess the mean population behavior, lacking resolution on drug-escaping cells. Inaccurate estimation of efficacy can lead to overestimation of compounds, whose efficacy will not be confirmed in the clinic, or lead to rejection of valuable candidates. Time-lapse microfluidic microscopy is a powerful approach to characterize drugs at high spatiotemporal resolution, but hard to apply on a large scale. Here we report the development of a microfluidic platform based on a pneumatic operating principle, which is scalable and compatible with long-term live-cell imaging and with simultaneous analysis of different drug concentrations. We tested the platform with mycobacterial cells, including the tubercular pathogen, providing the first proof of concept of a single-cell dose–response assay. This dynamic in-vitro model will prove useful to probe the fate of drug-stressed cells, providing improved predictions of drug efficacy in the clinic., This work was supported by the following Grants to G.M.: French Medical Research Foundation Grant ING20160435202; French National Research Agency Grant ANR-17-CE11-0007-01; French National Research Agency Grant ANR-10-LABX-62-IBEID; IMI 2 Joint Undertaking Grant 853989, receiving support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Global Alliance for TB Drug Development non-profit organization, Bill & Melinda Gates Foundation, University of Dundee; Institut Pasteur core funding.
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

Discovery of dual-active ethionamide boosters inhibiting the Mycobacterium tuberculosis ESX-1 secretion system

  • Gries, Raphael
  • Chhen, Jason
  • Gumpel, Edeltraud van
  • Theobald, Sebastian J.
  • Sonnenkalb, Linsay
  • Utpatel, Christian
  • Metzen, Fabian
  • Koch, Manuel
  • Dallenga, Tobias
  • Djaout, Kamel
  • Baulard, Alain
  • Dal Molin, Michael
  • Rybniker, Jan
Drug-resistant Mycobacterium tuberculosis (Mtb) remains a major public health concern requiring complementary approaches to standard anti-tuberculous regimens. Anti-virulence molecules or compounds that enhance the activity of antimicrobial prodrugs are promising alternatives to conventional antibiotics. Exploiting host cell-based drug discovery, we identified an oxadiazole compound (S3) that blocks the ESX-1 secretion system, a major virulence factor of Mtb. S3-treated mycobacteria showed impaired intracellular growth and a reduced ability to lyse macrophages. RNA sequencing experiments of drug-exposed bacteria revealed strong upregulation of a distinct set of genes including ethA, encoding a monooxygenase activating the anti-tuberculous prodrug ethionamide. Accordingly, we found a strong ethionamide boosting effect in S3-treated Mtb. Extensive structure-activity relationship experiments revealed that anti-virulence and ethionamide-boosting activity can be uncoupled by chemical modification of the primary hit molecule. To conclude, this series of dual-active oxadiazole compounds targets Mtb via two distinct mechanisms of action., J.R. is supported by the German Research Foundation (DFG) grant SFB 1403, the German Center for Infection Research (DZIF; TTU-TB grants 02.806, 02.814 and 02.913), the German Federal Ministry of Education and Research (BMBF, grant IdEpiCo) and by the European Union Innovative Medicines Initiative 2 Joint Undertaking program grant no. 853989 (ERA4TB). S.J.T. and J.R. are supported by a research grant of the CMMC (B10), and S.J.T. by stipends from the Imhoff-Stiftung and the Köln Fortune Program. A.B. is supported by the French Agence Nationale de la Recherche (ANR) Programme d’Investissement d’Avenir (Mustart ANR-20-PAMR-0005). L.S. is supported by the Research Training Group 2501 TransEvo.
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

High-throughput screening of small molecules targeting Mycobacterium tuberculosis in human iPSC macrophages

  • Armesilla Díaz, Alejandro
  • Arenaz, Maria Pilar
  • Ashby, Charlotte
  • Blanco, Delia
  • D'Oria, Emiliana
  • Garuti, Helena
  • Gómez, Vanesa
  • González Del Río, Rubén
  • Martínez Hoyos, María
  • Meiler, Eugenia
  • Mendoza Losana, Alfonso
  • Mohamet, Lisa
  • Padron Barthe, Laura
  • Pérez, Esther
  • Pérez, Laura
  • Remuiñán, Modesto J.
  • Rodriguez Miquel, Beatriz
  • Segura Carro, Delfina
  • Viera Morilla, Sara
New treatments are still necessary to eradicate tuberculosis disease. Macrophages derived from human induced pluripotent stem cells (hiPSC-Macs) offera physiological niche to identify potential new drugs in the context of Mycobacterium tuberculosis (Mtb) infection. Here, we describe the scale-up of hiPSC-Macs production in 5-stack chambers for high-throughput drug screening against Mtb. A rate of approximately 100 million hiPSC-Macs was generated with optimal quality for a period of up to 12 weeks. Moreover, the infection model was optimized using a luminescence-based Mtb reporter strain. The assay showed enough sensitivity to identify compounds that could target host-pathogen interactions during Mtb infection. We interrogated a library of 200,000 compounds in Mtb-infected hiPSC-Macs with a Z-score above 0.3 in all plates analyzed. After secondary assays, 223 qualifiedhits were selected for further progression., Funding Funder: European Commission Grants: Innovative Medicines Initiatives 2 Joint Undertaking (grant No 853989) Author(s): María Pilar Arenaz Delia Blanco Emiliana D'Oria Helena Garuti Vanesa Gómez Rubén González del Río María Martínez-Hoyos Eugenia Meiler Alfonso Mendoza-Losana Esther Pérez Laura Padrón-Barthe Modesto J. Remuiñán Beatriz Rodríguez-Miquel Delfina Segura-Carro Sara Viera-Morilla Funder: Ministerio de Ciencia, Innovación y Universidades Author(s): María Pilar Arenaz Delia Blanco Emiliana D'Oria Helena Garuti Vanesa Gómez Rubén González del Río María Martínez-Hoyos Eugenia Meiler Alfonso Mendoza-Losana, Esther Pérez Laura Pérez Modesto J. Remuiñán Beatriz Rodríguez-Miquel Delfina Segura-Carro Sara Viera-Morilla
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

Pharmacokinetics and safety of TBAJ-876, a novel antimycobacterial diarylquinoline, in healthy subjects

  • Lombardi, Antonio
  • Pappas, Fran
  • Nedelsman, Jerry
  • Hickman, Dean
  • Jaw-Tsai, Sarah
  • Olugbosi, Morounfolu
  • Bruinenberg, Paul
  • Beumont, Maria
  • Sun, Eugene
TBAJ-876, a second-generation diarylquinoline with greater antimycobacterial activity and a potentially better safety profile compared with bedaquiline, is under development for the treatment of drug-susceptible and drug-resistant tuberculosis (TB). A phase 1, first-in-human study of TBAJ-876, comprising a single-ascending dose (SAD) part including a food effect cohort, a multiple-ascending dose (MAD) part, and a relative bioavailability part of tablets versus oral suspension, was conducted on 137 healthy adults. A drug–drug interaction study was conducted on 28 healthy adults to evaluate the effects of TBAJ-876 on a cytochrome P450 3A4 substrate (midazolam) and a P-glycoprotein substrate (digoxin). TBAJ-876 was well-tolerated at single doses up to 800 mg and multiple doses up to 200 mg for 14 days. No deaths or serious adverse events occurred. No episodes of clinically significant prolongation of the QTc interval were observed. TBAJ-876 exposures were dose proportional in the SAD and MAD studies. TBAJ-876 exhibited multicompartmental pharmacokinetics (PK) with a long terminal half-life yielding quantifiable concentrations up to the longest follow-up of 10 weeks after a single dose and resulting in accumulation with multiple dosing. In the fed state, TBAJ-876 exposures approximately doubled with the tablet formulation, whereas M3 metabolite exposures decreased by approximately 20%. The relative bioavailability of TBAJ-876 was similar between tablets and the oral suspension at 100-mg doses. With co-administration of TBAJ-876, the AUC0-inf of midazolam was unchanged and the Cmax was reduced by 14%; the AUC0-last of digoxin was increased by 51%, and the Cmax was increased by 18%. These results support further investigation of TBAJ-876 for the treatment of tuberculosis., This work was supported by TB Alliance (Global Alliance for TB Drug Development) with funding from Australia’s Department of Foreign Affairs and Trade, Bill & Melinda Gates Foundation [OPP1129600], the Foreign, Commonwealth, and Development Office (United Kingdom), Germany’s Federal Ministry of Education and Research through KfW, Irish Aid, and the United States Agency for International Development.
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

From infection to immunity: understanding the response to SARS-CoV2 through in-silico modeling

  • Castiglione, Filippo
  • Deb, Debashrito
  • Srivastava, Anurag P.
  • Liò, Pietro
  • Liso, Arcangelo
Background: Immune system conditions of the patient is a key factor in COVID-19 infection survival. A growing number of studies have focused on immunological determinants to develop better biomarkers for therapies. Aim: Studies of the insurgence of immunity is at the core of both SARS-CoV-2 vaccine development and therapies. This paper attempts to describe the insurgence (and the span) of immunity in COVID-19 at the population level by developing an in-silico model. We simulate the immune response to SARS-CoV-2 and analyze the impact of infecting viral load, affinity to the ACE2 receptor, and age in an artificially infected population on the course of the disease. Methods: We use a stochastic agent-based immune simulation platform to construct a virtual cohort of infected individuals with age-dependent varying degrees of immune competence. We use a parameter set to reproduce known inter-patient variability and general epidemiological statistics. Results: By assuming the viremia at day 30 of the infection to be the proxy for lethality, we reproduce in-silico several clinical observations and identify critical factors in the statistical evolution of the infection. In particular, we evidence the importance of the humoral response over the cytotoxic response and find that the antibody titers measured after day 25 from the infection are a prognostic factor for determining the clinical outcome of the infection. Our modeling framework uses COVID-19 infection to demonstrate the actionable effectiveness of modeling the immune response at individual and population levels. The model developed can explain and interpret observed patterns of infection and makes verifiable temporal predictions. Within the limitations imposed by the simulated environment, this work proposes quantitatively that the great variability observed in the patient outcomes in real life can be the mere result of subtle variability in the infecting viral load and immune competence in the population. In this work, we exemplify how computational modeling of immune response provides an important view to discuss hypothesis and design new experiments, in particular paving the way to further investigations about the duration of vaccine-elicited immunity especially in the view of the blundering effect of immunosenescence., FC acknowledges partial funding from the European Union’s IMI 2 Joint Undertaking (JU) under grant agreement No. 853989 (project ERA4TB) and from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 826121 (project iPC).
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

Population pharmacokinetics of TBAJ-587 and its main metabolites—Evaluation of different loading dose strategies and early dose selection

  • Leding, Albin A. M.
  • Bruinenberg, Paul
  • Conradie, Almari
  • Nedelman, Jerry
  • Lombardi, Antonio
  • Hickman, Dean
  • Simonsson, Ulrika S. H.
Background and Aim: The rise of drug-resistant tuberculosis (TB) poses a need for new drugs and combinations. TBAJ-587, a new diarylquinoline (DARQ), has shown promising efficacy in preclinical studies. This work aimed to describe the pharmacokinetics (PK) of TBAJ-587 and its metabolites M2 and M3 after single ascending dosing in healthy volunteers and to develop a simultaneous population PK model. In addition, to explore different doses in relation to efficacy and safety and to assess the impact of loading doses on exposure levels of TBAJ-587 and its metabolites. Methods: Pharmacokinetic samples from 42 healthy volunteers following a single dose (25, 50, 100, 200, 400 or 800 mg) were collected for up to Day 126. Population pharmacokinetic modelling was conducted using nonlinear mixed-effects modelling in NONMEM. Simulations from final model were performed to compare against efficacy targets derived from the first-in-class DARQ bedaquiline and safety references based on preclinical studies. Results and Conclusions: The final model simultaneously described the PK of TBAJ-587, M2 and M3 well. Simulations of final model identified that all simulated doses and regimens resulted in exposures that were below the safety references. A loading dose for 2 weeks resulted in initially higher concentrations, but a limited difference in exposure at 4 weeks and onwards, compared with no loading dose. A 100 mg once daily dose and higher reached the efficacy targets and can be studied further in combinations in phase 2a studies. Name of trial: Evaluation of the Safety, Tolerability, PK of TBAJ-587 in Healthy Adults. Registration number: NCT04890535., The project leading to this publication has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under Grant 853989. The JU receives support from the European Union's Horizon 2020 Research and Innovation Programme, EFPIA, Global Alliance for TB Drug Development Non-Profit Organization, Bill & Melinda Gates Foundation and University of Dundee. Link to the website: http://www.imi.europa.eu. This work reflects only the author's views, and the JU is not responsible for any use that may be made of the information it contains. The computations were enabled by resources in projects NAISS 2023/5-492 and NAISS 2023/23-591 provided by the National Academic Infrastructure for Supercomputing in Sweden (NAISS) at UPPMAX, funded by the Swedish Research Council through Grant 2022-06725.
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium

  • van Wijk, Rob C.
  • Lucía, Ainhoa
  • Kumar Sudhakar, Pavan
  • Sonnenkalb, Lindsay
  • Gaudin, Cyril
  • Hoffmann, Eik
  • Dremierre, Bérénice
  • Aguilar-Ayala, Diana Angélica
  • Dal Molin, Michael
  • Rybniker, Jan
  • de Giorgi, Stefano
  • Cioetto-Mazzabò, Laura
  • Segafreddo, Greta
  • Manganelli, Riccardo
  • Degiacomi, Giulia
  • Recchia, Deborah
  • Pasca, Maria Rosalia
  • Simonsson, Ulrika S.H.
  • Ramoón-García, Santiago
Tuberculosis (TB) is the historical leading cause of death by a single infectious agent. The European Regimen Accelerator for Tuberculosis (ERA4TB) is a public- private partnership of 30+ institutions with the objective to progress new anti-TB regimens into the clinic. Thus, robust and replicable results across independent laboratories are essential for reliable interpretation of treatment efficacy. A standardization workgroup unified in vitro protocols and data reporting templates. Time-kill assays provide essential input data for pharmacometric model-informed translation of single agents and regimens activity from in vitro to in vivo and the clinic. Five conditions were assessed by time-kill assays in six independent laboratories using four bacterial plating methods. Baseline bacterial burden varied between laboratories but variability was limited in net drug effect, confirming 2.5 mL equally robust as 100 mL plating. This exercise establishes the foundations of collaborative data generation, reporting, and integration within the overarching Antimicrobial Resistance Accelerator program., The project leading to this publication has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853989. The JU receives support from the European Union’s Horizon 2020 Research and Innovation Program and EFPIA and Global Alliance for TB Drug Development Non-Profit Organisation, Bill & Melinda Gates Foundation, University of Dundee. This work reflects only the author’s views, and the JU is not responsible for any use that may be made of the information it contains.
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

A candidate multi-epitope vaccine against SARS-CoV-2

  • Kar, Tamalika
  • Narsaria, Utkarsh
  • Basak, Srijita
  • Deb, Debashrito
  • Castiglione, Filippo
  • Mueller, David M.
  • Srivastava, Anurag P.
In the past two decades, 7 coronaviruses have infected the human population, with two major outbreaks caused by SARS-CoV and MERS-CoV in the year 2002 and 2012, respectively. Currently, the entire world is facing a pandemic of another coronavirus, SARS-CoV-2, with a high fatality rate. The spike glycoprotein of SARS-CoV-2 mediates entry of virus into the host cell and is one of the most important antigenic determinants, making it a potential candidate for a vaccine. In this study, we have computationally designed a multi-epitope vaccine using spike glycoprotein of SARS-CoV-2. The overall quality of the candidate vaccine was validated in silico and Molecular Dynamics Simulation confirmed the stability of the designed vaccine. Docking studies revealed stable interactions of the vaccine with Toll-Like Receptors and MHC Receptors. The in silico cloning and codon optimization supported the proficient expression of the designed vaccine in E. coli expression system. The efficiency of the candidate vaccine to trigger an effective immune response was assessed by an in silico immune simulation. The computational analyses suggest that the designed multi-epitope vaccine is structurally stable which can induce specific immune responses and thus, can be a potential vaccine candidate against SARS-CoV-2., The authors thank Dr. Joseph V.G., Chancellor Garden City University for his constant support to carry out this research work. FC acknowledges partial support from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 853989 (Project ERA4TB). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA and Global Alliance for TBDrug Development non profit organization Bill & D.M.Melinda Gates Foundation and University of Dundee. D.M.M was supported by a grant from NIH, R35 GM131731.
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

RHBDL4-triggered downregulation of COPII adaptor protein TMED7 suppresses TLR4-mediated inflammatory signaling

  • Knopf, Julia D.
  • Steigleder, Susanne S.
  • Korn, Friederike
  • Kühnle, Nathalie
  • Badenes, Marina
  • Tauber, Marina
  • Theobald, Sebastian J.
  • Rybniker, Jan
  • Adrain, Colin
  • Lemberg, Marius K.
The toll-like receptor 4 (TLR4) is a central regulator of innate immunity that primarily recognizes bacterial lipopolysaccharide cell wall constituents to trigger cytokine secretion. We identify the intramembrane protease RHBDL4 as a negative regulator of TLR4 signaling. We show that RHBDL4 triggers degradation of TLR4’s trafficking factor TMED7. This counteracts TLR4 transport to the cell surface. Notably, TLR4 activation mediates transcriptional upregulation of RHBDL4 thereby inducing a negative feedback loop to reduce TLR4 trafficking to the plasma membrane. This secretory cargo tuning mechanism prevents the over-activation of TLR4-dependent signaling in an in vitro Mycobacterium tuberculosis macrophage infection model and consequently alleviates septic shock in a mouse model. A hypomorphic RHBDL4 mutation linked to Kawasaki syndrome, an ill-defined inflammatory disorder in children, further supports the pathophysiological relevance of our findings. In this work, we identify an RHBDL4-mediated axis that acts as a rheostat to prevent over-activation of the TLR4 pathway., The work was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – Project-ID 201348542 – CRC 1036/TP12, the Center of Molecular Medicine Cologne (CMMC) – Project-ID C10, and a fellowship of the Boehringer Ingelheim Fonds to J.D.K. J.R. is supported by the German Research Foundation (DFG) grant SFB 1403, the German Center for Infection Research (DZIF; TTU-TB grants 02.806, 02.814 and 02.913), the German Federal Ministry of Education and Research BMBF, grant IdEpiCo and by the European Union Innovative Medicines Initiative 2 Joint Undertaking program grant no. 853989 (ERA4TB). S.J.T. and J.R. are supported by a research grant of the CMMC (B10), and S.J.T. by stipends from the Imhoff-Stiftung and the Köln Fortune Program. Open Access funding enabled and organized by Projekt DEAL.
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

Mechanopathology of biofilm-like Mycobacterium tuberculosis cords

  • Mishra, Richa
  • Hannebelle, Melanie
  • Patil, Vishal P.
  • Dubois, Anaëlle
  • Garcia-Mouton, Cristina
  • Kirsch, Gabriela M.
  • Jan, Maxime
  • Sharma, Kunal
  • Guex, Nicolas
  • Sordet-Dessimoz, Jessica
  • Pérez-Gil, Jesís
  • Prakash, Manu
  • Knott, Graham W.
  • Dhar, Neeraj
  • McKinney, John D.
  • Thacker, Vivek V.
Mycobacterium tuberculosis (Mtb) cultured axenically without detergent forms biofilm-like cords, a clinical identifier of virulence. In lung-on-chip (LoC) and mouse models, cords in alveolar cells contribute to suppression of innate immune signaling via nuclear compression. Thereafter, extracellular cords cause contact-dependent phagocyte death but grow intercellularly between epithelial cells. The absence of these mechanopathological mechanisms explains the greater proportion of alveolar lesions with increased immune infiltration and dissemination defects in cording-deficient Mtb infections. Compression of Mtb lipid monolayers induces a phase transition that enables mechanical energy storage. Agent-based simulations demonstrate that the increased energy storage capacity is sufficient for the formation of cords that maintain structural integrity despite mechanical perturbation. Bacteria in cords remain translationally active despite antibiotic exposure and regrow rapidly upon cessation of treatment. This study provides a conceptual framework for the biophysics and function in tuberculosis infection and therapy of cord architectures independent of mechanisms ascribed to single bacteria., V.P.P. acknowledges support from a Stanford Science Fellowship. C.G.-M. acknowledges scholarships from the Spanish Ministry of Science, Innovation and Universities (FPU16/02553 and EST19/00993). J.P.-G. acknowledges support from the Spanish Ministry of Economy and Competitiveness (RTI2018-094564-B-100) and from the Regional Government of Madrid (P2018/NMT-4389). M.P. acknowledges support from the Howard Hughes Medical Institute (HHMI) Faculty Fellows Program. This research was supported by grants to J.D.M. from the SNSF (310030B_176397 and 310030_207717) and to N.D. and J.D.M. from the European Regimen Accelerator for Tuberculosis (ERA4TB), funded by the Innovative Medicines Initiative 2 Joint Undertaking (853989). V.V.T. acknowledges support by Long-Term Fellowships from the Human Frontier Science Program (HFSP, LT000231/2016-L), the European Molecular Biology Organization (EMBO, 921-2015), a grant from the Novartis Foundation for Medical-Biological Research (#20C240), and the Holcim Stiftung zur Förderung der Wissenschaftlichen. Author contributions
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

Difference in persistent tuberculosis bacteria between in vitro and sputum from patients: implications for translational predictions

  • Faraj, Alan
  • Clewe, Oskar
  • Svensson, Robin J.
  • Mukamolova, Galina V.
  • Barer, Michael R.
  • Simonsson, Ulrika S. H.
This study aimed to investigate the number of persistent bacteria in sputum from tuberculosis patients compared to in vitro and to suggest a model-based approach for accounting for the potential difference. Sputum smear positive patients (n = 25) provided sputum samples prior to onset of chemotherapy. The number of cells detected by conventional agar colony forming unit (CFU) and most probable number (MPN) with Rpf supplementation were quantified. Persistent bacteria was assumed to be the difference between MPNrpf and CFU. The difference in persistent bacteria between in vitro and human sputum prior to chemotherapy was quantified using different model-based approaches. The persistent bacteria in sputum was 17% of the in vitro levels, suggesting a difference in phenotypic resistance, whereas no difference was found for multiplying bacterial subpopulations. Clinical trial simulations showed that the predicted time to 2 log fall in MPNrpf in a Phase 2a setting using in vitro pre-clinical efficacy information, would be almost 3 days longer if drug response was predicted ignoring the difference in phenotypic resistance. The discovered phenotypic differences between in vitro and humans prior to chemotherapy could have implications on translational efforts but can be accounted for using a model-based approach for translating in vitro to human drug response., This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853989. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Global Alliance for TB Drug Development non profit organisation, Bill & Melinda Gates Foundation and University of Dundee. The authors also would like to acknowledge the patients involved in the trial for their contribution to the research.
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

An assay toolkit for anti-tuberculosis drugs in the hollow fiber system

  • Sanz-García, Fernando
  • Ndjogou, Dominique
  • Aguilar-Ayala, Diana A.
  • Eveque-Mourroux, Maxime R.
  • Benítez, Ana
  • Aznar, Sergio
  • Isach-Traver, Nuria
  • Mendoza Losana, Alfonso
  • Willand, Nicolas
  • Quintana, Ainhoa Lucía
  • Ramón García, Santiago
The hollow-fiber system for tuberculosis (HFS-TB) is an in vitro pharmacokinetic/pharmacodynamic (PKPD) tool qualified by the European Medicines Agency to support anti-TB drug development. It can simulate PK parameters of antimicrobials and feed in silico models to inform phase II/III clinical trials. Yet, its implementation is challenging due to lack of consolidated technical guidelines, such as the compatibility of drugs with the most commonly used types of HFS-TB cartridges. Herein, we uncovered the compatibility of 10 anti-TB drugs alone: bedaquiline, clarithromycin, delamanid, ethambutol, isoniazid, linezolid, moxifloxacin, pretomanid, rifampicin, and rifapentine; and of a combination, bedaquiline-pretomanid-linezolid. The most hydrophilic compounds were within the compatibility range with all fibers; whereas the lipophilic ones required adjustments to be used in the system. Also, polysulfone and cellulose fibers were the most suitable for the tested drugs. Our data strengthen the importance of these preliminary studies and provide a useful toolkit toward wider HFS-TB implementation., We would like to thank the technical support of Ana Picó Marco from the University of Zaragoza, Spain, and the recommendations on targeted PK parameters for BPaL combination of Evangelos Karakitsios from Institute for Applied Computing “Mauro Picone,” Consiglio Nazionale delle Ricerche, Italy. This work has received support from the Innovative Medicines Initiatives 2 Joint Undertaking (JU) under grant agreement No 853989 to N.W. and S.R.-G. The JU receives support from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA, Global Alliance for TB Drug Development Non-Profit Organisation, Bill & Melinda Gates Foundation and University of Dundee.
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

Tolerance and Persistence to Drugs: A Main Challenge in the Fight Against Mycobacterium tuberculosis

  • Boldrin, Francesca
  • Provvedi, Roberta
  • Mazzabò Cioetto, Laura
  • Segafreddo, Greta
  • Manganelli, Riccardo
The treatment of tuberculosis is extremely long. One of the reasons why Mycobacterium tuberculosis elimination from the organism takes so long is that in particular environmental conditions it can become tolerant to drugs and/or develop persisters able to survive killing even from very high drug concentrations. Tolerance develops in response to a harsh environment exposure encountered by bacteria during infection, mainly due to the action of the immune system, whereas persistence results from the presence of heterogeneous bacterial populations with different degrees of drug sensitivity, and can be induced by exposure to stress conditions. Here, we review the actual knowledge on the stress response mechanisms enacted by M. tuberculosis during infection, which leads to increased drug tolerance or development of a highly drug-resistant subpopulation., RM laboratory is founded from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement no 853989. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and “EFPIA and Global Alliance for Tb Drug Development Non Profit Organization, Bill & Melinda Gates Foundation, University of Dundee.”
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

RNase E and HupB dynamics foster mycobacterial cell homeostasis and fitness

  • Griego, Anna
  • Douche, Thibaut
  • Giai Gianetto, Quentin
  • Matondo, Mariette
  • Manina, Giulia
RNA turnover is a primary source of gene expression variation, in turn promoting cellular adaptation. Mycobacteria leverage reversible mRNA stabilization to endure hostile conditions. Although RNase E is essential for RNA turnover in several species, its role in mycobacterial single-cell physiology and functional phenotypic diversification remains unexplored. Here, by integrating live-singlecell and quantitative-mass-spectrometry approaches, we show that RNase E forms dynamic foci, which are associated with cellular homeostasis and fate, and we discover a versatile molecular interactome. We show a likely interaction between RNase E and the nucleoid-associated protein HupB, which is particularly pronounced during drug treatment and infection, where phenotypic diversity increases. Disruption of RNase E expression affects HupB levels, impairing Mycobacterium tuberculosis growth homeostasis during treatment, intracellular replication, and host spread. Our work lays the foundation for targeting the RNase E and its partner HupB, aiming to undermine M. tuberculosis cellular balance, diversification capacity, and persistence., We thank Blaise Li (Institut Pasteur Bioinformatics and Biostatistics Hub), for support in writing a python script for sorting image analysis data. We thank Delphine Vergoz for her contribution to constructing the DVS2 strain. This work was funded by grants to G.M. from the French National Research Agency (ANR-17-CE11-0007-01; ANR-10-LABX-62-IBEID). This project also received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853989. The JU receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA and Global Alliance for TB Drug Development non-profit organization, Bill & Melinda Gates Foundation, University of Dundee. Work in G.M.’s laboratory also received financial support from the Institut Pasteur and a donation from Mr. Lacoste.
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

Computer-aided diagnostic for classifying chest X-ray images using deep ensemble learning

  • Visuña, Lara
  • García Blas, Francisco Javier
  • Yang, Dandi
  • Carretero Pérez, Jesús
Background: Nowadays doctors and radiologists are overwhelmed with a huge amount of work. This led to the effort to design different Computer-Aided Diagnosis systems (CAD system), with the aim of accomplishing a faster and more accurate diagnosis. The current development of deep learning is a big opportunity for the development of new CADs. In this paper, we propose a novel architecture for a convolutional neural network (CNN) ensemble for classifying chest X-ray (CRX) images into four classes: viral Pneumonia, Tuberculosis, COVID-19, and Healthy. Although Computed tomography (CT) is the best way to detect and diagnoses pulmonary issues, CT is more expensive than CRX. Furthermore, CRX is commonly the first step in the diagnosis, so it’s very important to be accurate in the early stages of diagnosis and treatment. Results: We applied the transfer learning technique and data augmentation to all CNNs for obtaining better performance. We have designed and evaluated two different CNN-ensembles: Stacking and Voting. This system is ready to be applied in a CAD system to automated diagnosis such a second or previous opinion before the doctors or radiology’s. Our results show a great improvement, 99% accuracy of the Stacking Ensemble and 98% of accuracy for the the Voting Ensemble. Conclusions: To minimize missclassifications, we included six different base CNN models in our architecture (VGG16, VGG19, InceptionV3, ResNet101V2, DenseNet121 and CheXnet) and it could be extended to any number as well as we expect extend the number of diseases to detected. The proposed method has been validated using a large dataset created by mixing several public datasets with different image sizes and quality. As we demonstrate in the evaluation carried out, we reach better results and generalization compared with previous works. In addition, we make a first approach to explainable deep learning with the objective of providing professionals more information that may be valuable when evaluating CRXs., This work was supported by the Innovative Medicines Initiative 2 Joint Undertaking (JU) under Grant Agreement No. 853989. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and Global Alliance for TB Drug Development non-profit organisation, Bill & Melinda Gates Foundation and University of Dundee.
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

Detection and analysis of COVID-19 in medical images using deep learning techniques

  • Yang, Dandi
  • Martinez Rendon, Cristhian
  • Visuña, Lara
  • Khandhar, Hardev
  • Bhatt, Chintan
  • Carretero Pérez, Jesús
The main purpose of this work is to investigate and compare several deep learning enhanced techniques applied to X-ray and CT-scan medical images for the detection of COVID-19. In this paper, we used four powerful pre-trained CNN models, VGG16, DenseNet121, ResNet50,and ResNet152, for the COVID-19 CT-scan binary classification task. The proposed Fast.AI ResNet framework was designed to find out the best architecture, pre-processing, and training parameters for the models largely automatically. The accuracy and F1-score were both above 96% in the diagnosis of COVID-19 using CT-scan images. In addition, we applied transfer learning techniques to overcome the insufficient data and to improve the training time. The binary and multi-class classification of X-ray images tasks were performed by utilizing enhanced VGG16 deep transfer learning architecture. High accuracy of 99% was achieved by enhanced VGG16 in the detection of X-ray images from COVID-19 and pneumonia. The accuracy and validity of the algorithms were assessed on X-ray and CT-scan well-known public datasets. The proposed methods have better results for COVID-19 diagnosis than other related in literature. In our opinion, our work can help virologists and radiologists to make a better and faster diagnosis in the struggle against the outbreak of COVID-19., The research leading to these results received funding from the Innovative Medicines Innitiative 2 Joint Undertaking (JU) under grant agreement No 853989. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and Global Alliance for TB Drug Development non profit organisation, Bill & Melinda Gates Foundation and University of Dundee.
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

In silico designing of vaccine candidate against Clostridium difficile

  • Basak, Srijita
  • Deb, Debashrito
  • Narsaria, Utkarsh
  • Kar, Tamalika
  • Castiglione, Filippo
  • Sanyal, Indraneel
  • Bade, Pratap D.
  • Srivastava, Anurag P.
Clostridium difficile is a spore-forming gram-positive bacterium, recognized as the primary cause of antibiotic-associated nosocomial diarrhoea. Clostridium difficile infection (CDI) has emerged as a major health-associated infection with increased incidence and hospitalization over the years with high mortality rates. Contamination and infection occur after ingestion of vegetative spores, which germinate in the gastro-intestinal tract. The surface layer protein and flagellar proteins are responsible for the bacterial colonization while the spore coat protein, is associated with spore colonization. Both these factors are the main concern of the recurrence of CDI in hospitalized patients. In this study, the CotE, SlpA and FliC proteins are chosen to form a multivalent, multi-epitopic, chimeric vaccine candidate using the immunoinformatics approach. The overall reliability of the candidate vaccine was validated in silico and the molecular dynamics simulation verified the stability of the vaccine designed. Docking studies showed stable vaccine interactions with Toll‐Like Receptors of innate immune cells and MHC receptors. In silico codon optimization of the vaccine and its insertion in the cloning vector indicates a competent expression of the modelled vaccine in E. coli expression system. An in silico immune simulation system evaluated the effectiveness of the candidate vaccine to trigger a protective immune response., F.C. wish to thank the Italian Ministry of Education, University and Research, for partial support under the frame of JPI AMR (project MAGIcIAN, N. 0000873) and the European Commission for partial support under the IMI 2 Joint Undertaking (project ERA4TB, Grant agreement N. 853989).
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

Development of an Inverted Epifluorescence Microscope for Long-Term Monitoring of Bacteria in Multiplexed Microfluidic Devices

  • Torres Simón, Amaro
  • Marino Miguélez, María Henar
  • Gómez Cruz, Clara
  • Cañadas Ortega, Marina
  • Marco Esteban, Miguel
  • Ripoll Lorenzo, Jorge
  • Vaquero López, Juan José
  • Muñoz Barrutia, María Arrate
Developing more efficient methods for antibiotic susceptibility testing is a pressing issue in novel drug development as bacterial resistance to antibiotics becomes increasingly common. Microfluidic devices have been demonstrated to be powerful platforms that allow researchers to perform multiplexed antibiotic testing. However, the level of multiplexing within microdevices is limited, evidencing the need of creating simple, low-cost and high-resolution imaging systems that can be integrated in antibiotic development pipelines. This paper describes the design and development of an epifluorescence inverted microscope that enables long-term monitoring of bacteria inside multiplexed microfluidic devices. The goal of this work is to provide a simple microscope powerful enough to allow single-cell analysis of bacteria at a reduced cost. This facilitates increasing the number of microscopes that are simultaneously used for antibiotic testing. We prove that the designed system is able to accurately detect fluorescent beads of 100 nm, demonstrating comparable features to high-end commercial microscopes and effectively achieving the resolution required for single-cell analysis of bacteria. The proposed microscope could thus increase the efficiency in antibiotic testing while reducing cost, size, weight, and power requirements, contributing to the successful development of new antibiotic drugs., This work was partially funded by project TEC2016-78052-R from the Spanish Ministry of Economy and PID2019-109820RB-I00 from the Spanish Ministry of Science and Innovation. The research leading to these results received funding from the Innovative Medicines Innitiative 2 Joint Undertaking (JU) under grant agreement No 853989. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Global Alliance for TB Drug Development non profit organisation, Bill & Melinda Gates Foundation and University of Dundee.
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

Genomic and phenotypic characterization of Mycobacterium tuberculosis’ closest-related non-tuberculous mycobacteria

  • Sous, Camille
  • Frigui, Wafa
  • Pawlik, Alexandre
  • Sayes, Fadel
  • Ma, Laurence
  • Cokelaer, Thomas
  • Brosch, Roland
Four species of non-tuberculous mycobacteria (NTM) rated as biosafety level 1 or 2 (BSL-1/BSL-2) organisms and showing higher genomic similarity with Mycobacterium tuberculosis (Mtb) than previous comparator species Mycobacterium kansasii and Mycobacterium marinum were subjected to genomic and phenotypic characterization. These species named Mycobacterium decipiens, Mycobacterium lacus, Mycobacterium riyadhense, and Mycobacterium shinjukuense might represent “missing links” between low-virulent mycobacterial opportunists and the highly virulent obligate pathogen Mtb. We confirmed that M. decipiens is the closest NTM species to Mtb currently known and found that it has an optimal growth temperature of 32°C–35°C and not 37°C. M. decipiens showed resistance to rifampicin, isoniazid, and ethambutol, whereas M. lacus and M. riyadhense showed resistance to isoniazid and ethambutol. M. shinjukuense was sensitive to all three first-line TB drugs, and all four species were sensitive to bedaquiline, a third-generation anti-TB drug. Our results suggest these four NTM may be useful models for the identification and study of new anti-TB molecules, facilitated by their culture under non-BSL-3 conditions as compared to Mtb. M. riyadhense was the most virulent of the four species in cellular and mouse infection models. M. decipiens also multiplied in THP-1 cells at 35°C but was growth impaired at 37°C. Genomic comparisons showed that the espACD locus, essential for the secretion of ESX-1 proteins in Mtb, was present only in M. decipiens, which was able to secrete ESAT-6 and CFP-10, whereas secretion of these antigens varied in the other species, making the four species interesting examples for studying ESX-1 secretion mechanisms., Support by grants from the Agence National de Recherche (ANR-10-LABX-62-IBEID and ANR-20-CE15-0013) is gratefully acknowledged. The project leading to this publication has also received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 853989. The JU receives support from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA and Global Alliance for TB Drug Development Non-Profit Organisation, Bill & Melinda Gates Foundation, University of Dundee. This communication reflects the author’s view, and neither IMI nor the European Union or EFPIA is responsible for any use that may be made of the information contained therein. The Biomics Platform, C2RT, at the Institut Pasteur, Paris, France is supported by France Génomique (ANR-10-INBS-09) and IBISA. The LABGeM (CEA/Genoscope and CNRS UMR8030), the France Génomique, and French Bioinformatics Institute national infrastructures (funded as part of Investissement d'Avenir program managed by Agence Nationale pour la Recherche, contracts ANR-10-INBS-09 and ANR-11-INBS-0013) are acknowledged for support within the MicroScope annotation platform.
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Reseña (Review)

Evolution and emergence of Mycobacterium tuberculosis

  • Orgeur, Mickael
  • Sous, Camille
  • Madacki, Jan
  • Brosch, Roland
Tuberculosis (TB) remains one of the deadliest infectious diseases in human history, prevailing even in the 21st century. The causative agents of TB are represented by a group of closely related bacteria belonging to the Mycobacterium tuberculosis complex (MTBC), which can be subdivided into several lineages of human- and animal-adapted strains, thought to have shared a last common ancestor emerged by clonal expansion from a pool of recombinogenic Mycobacterium canettii-like tubercle bacilli. A better understanding of how MTBC populations evolved from less virulent mycobacteria may allow for discovering improved TB control strategies and future epidemiologic trends. In this review, we highlight new insights into the evolution of mycobacteria at the genus level, describing different milestones in the evolution of mycobacteria, with a focus on the genomic events that have likely enabled the emergence and the dominance of the MTBC. We also review the recent literature describing the various MTBC lineages and highlight their particularities and differences with a focus on host preferences and geographic distribution. Finally, we discuss on putative mechanisms driving the evolution of tubercle bacilli and mycobacteria in general, by taking the mycobacteria-specific distributive conjugal transfer as an example., Support by grants from the Agence National de Recherche [ANR-10-LABX-62-IBEID and ANR-20-CE15-0013] is gratefully acknowledged. The project leading to this publication has also received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853989. The JU receives support from the European Union’s Horizon 2020 Research and Innovation Programme and EFPIA and Global Alliance for TB Drug Development Non-Profit Organisation, Bill & Melinda Gates Foundation, University of Dundee.
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

Incidence and risk factors for HIV-tuberculosis coinfection in the Cologne–Bonn region: a retrospective cohort study

  • Suárez, Isabelle
  • Rauschning, Dominic
  • Schüller, Cora
  • Hagemeier, Anna
  • Stecher, Melanie
  • Lehmann, Clara
  • Schommers, Philipp
  • Schlabe, Stefan
  • Vehreschild, Jörg-Janne
  • Koll, Carolin
  • Schwarze-Zander, Carolynne
  • Wasmuth, Jan-Christian
  • Klingmüller, Angela
  • Rockstroh, Jürgen Kurt
  • Fätkenheuer, Gerd
  • Boesecke, Christoph
  • Rybniker, Jan
Purpose: The risk of developing active tuberculosis (TB) is considerably increased in people living with HIV/AIDS (PLWH). However, incidence of HIV/TB coinfection is difficult to assess as surveillance data are lacking in many countries. Here, we aimed to perform a quantitative analysis of HIV/TB coinfections within the Cologne/Bonn HIV cohort and to determine risk factors for active TB. Methods: We systematically evaluated data of patients with HIV/TB coinfection between 2006 and 2017. In this retrospective analysis, we compared HIV/TB-coinfected patients with a cohort of HIV-positive patients. The incidence density rate (IDR) was calculated for active TB cases at different time points. Results: During 2006–2017, 60 out of 4673 PLWH were diagnosed with active TB. Overall IDR was 0.181 cases/100 patient-years and ranged from 0.266 in 2006–2009 to 0.133 in 2014–2017. Patients originating from Sub-Saharan Africa had a significantly (p < 0.001) higher IDR (0.694/100 patient-years of observation, 95% CI [0.435–1.050]) in comparison to patients of German origin (0.053/100 patient-years of observation, 95% CI [0.028–0.091]). In terms of TB-free survival, individuals originating from countries with a TB incidence higher than 10/100,000 exhibited a markedly reduced TB-free survival compared to those originating from regions with lower incidence (p < 0.001). In 22 patients, TB and HIV infection were diagnosed simultaneously. Conclusion: Overall, we observed a decline in the incidence density rate (IDR) of HIV/TB coinfections between 2006 and 2017. Patients originating from regions with high incidence bear a higher risk of falling ill with active TB. For PLWH born in Germany, the observed risk of active TB appears to be lower compared to other groups within the cohort. These findings should be considered when developing TB containment and screening strategies for PLWH in low-incidence countries., Open Access funding enabled and organized by Projekt DEAL. JR is supported by the German Research Foundation (DFG) grant SFB 1403; the German Center for Infection Research (DZIF) grant TTU 02.806 and by the Innovative Medicines Initiative 2 Joint Undertaking Grant agreement No. 853989 (ERA4TB). GF has received research grants from the German Federal Ministry of Education and Research (BMBF) 01KI1017 and 01KG0915 and is supported by the German Centre for Infection Research (DZIF). IS was supported by the German Centre for Infection Research (DZIF) (grant number TI 07.001_SUAREZ_00 and TTU2.913_00) and the Federal Joint Committee (G-BA, German Federal Ministry of Health).
e-Archivo. Repositorio Institucional de la Universidad Carlos III de Madrid
Publicación Artículo científico (JournalArticle)

Automated monitoring of Mycobacterium population growth in time-lapse microscopy with Deep Learning pseudo-supervised algorithm

  • Visuña, Lara
  • García Blas, Francisco Javier
  • Ferrer Bazaga, Santiago
  • López Expósito, Patricio Roberto
  • Carretero Pérez, Jesús
The understanding of bacteria evolution through time and the analysis of their interaction with the medium is a main step in biomedical research. Bacteria cause in humans different infectious diseases, such as tuberculosis. Tuberculosis is one of the leading causes of death worldwide, caused by Mycobacterium tuberculosis (Mtb). Observation of Mycobacteria under a microscope provides essential information for disease-fighting. Nevertheless, Mtb presents a very particular cell division pattern characterized by a high entanglement in which the frontier between dividing cells are almost indistinguishable to the human eye, which makes the manual analysis of cultures a very challenging task, resulting in extremely long processing times. In this paper, we propose a novel approach to automatically detect bacterial cells and infer the growth rate and growth speed over a time-lapse microscopy (TLM) sequence. This method leverages a semi-supervised Deep Learning approach with a lightweight U-Net for efficient and fast processing. To reduce efforts of database construction, we deploy and exploit a mix of manually and synthetically annotated databases of two different classes of Mycobacterium, i.e. Mtb and Mycobacterium smegmatis (Msm). The experiments demonstrated the efficiency of the detection of both bacterial reproduction rate and bacterial death in Mycobacterium species, with the Phase-contrast (PhC) microscopy channels as a unique input. Reaching a segmentation accuracy of 96.3%, recall of 78.2%, and precision of 85.5% on Mtb detection for the model trained with a mix of manually and synthetically annotated databases. The experiments validate as well the synthetic label generation technique, which provides more conscience and accurate results than the manually segmented techniques. The mask generation workflow opens new opportunities for the microbial AI development field. The system implemented may change the paradigm in preclinical anti-mycobacteria drug development for since enables the adoption of TLM, a technology that provides extremely valuable information on drug efficacy but is seldom leveraged due to the complex image processing it involves., This work was supported by the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853989. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and Global Alliance for TB Drug Development non-profit organization, Bill & Melinda Gates Foundation, United States and University of Dundee, United Kingdom
Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Artículo científico (JournalArticle)

Academia and industry agreement on a feasibility tool for first-time-in-human clinical trial units

  • Moraga, Paloma
  • Prieto, Paula
  • Davy, Maria
  • Portolés, Antonio
  • Borobia Pérez, Alberto M.
  • Conradie, Almari
  • Rousell, Vicki
  • Benhayoun, Majda
  • Antonijoan Arbos, Rosa
  • Abad Santos, Francisco
  • Carcas Sansuán, Antonio Javier
  • Fuhr, Uwe
  • Van Duinen, Jolanda
First-time-in-human (FTIH) trials are designed to generate information on the safety, tolerability, as well as the pharmacokinetic and pharmacodynamics profile of new drugs. To ensure the safety of participants, these trials need to be conducted at specifically equipped phase I clinical trial units (CTUs). In accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guideline for Good Clinical Practice (GCP) and the European Union (EU) regulatory guidelines, one of the aims of the European Regime Accelerator for Tuberculosis (ERA4TB) project is to collaboratively create a feasibility tool, through a partnership between public and private entities, for the validation of CTUs selected to conduct FTIH trials. A feasibility form, encompassing nine sections, was created to gather information on the unit in relation to key attributes of FTIH trials. Collaboratively, industry and academic partners defined the minimal criteria to ensure the adherence of CTUs to the principles of ICH GCP and regulations outlined by the European Medicines Agency (EMA) for the execution of FTIH trials. Subsequently, all CTUs available for the project were assessed for FTIH trial eligibility. The introduction of the certification procedure through the feasibility tool within ERA4TB resulted in the accreditation of the five academic CTUs, which are now prepared to carry out FTIH trials as part of the Consortium. The developed feasibility tool aims to establish open and widely used minimum requirements for the validation of academic CTUs as FTIH units, marking it as the inaugural tool for CTU validation resulting from the collaboration between industry and academia within the ERA4TB project. The established partnership has enabled an innovative and novel way of working, The project leading to this publication has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 853989. The JU receives support from the European Union's Horizon 2020 Research and Innovation Programme and EFPIA and Global Alliance for TB Drug Development Non-Profit Organization, the Bill & Melinda Gates Foundation, and the University of Dundee
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Implementing best practises on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium

  • van Wijk, Rob C.
  • Lucía, Ainhoa
  • Sudhakar, Pavan Kumar
  • Sonnenkalb, Lindsay
  • Gaudin, Cyril
  • Hoffmann, Eik
  • Dremierre, Bérénice
  • Aguilar-Ayala, Diana Angélica
  • Dal Molin, Michael
  • Rybniker, Jan
  • de Giorgi, Stefano
  • Cioetto-Mazzabò, Laura
  • Segafreddo, Greta
  • Manganelli, Riccardo
  • Degiacomi, Giulia
  • Recchia, Deborah
  • Pasca, Maria Rosalia
  • Simonsson, Ulrika S. H.
  • Ramón-García, Santiago
Tuberculosis (TB) is the historical leading cause of death by a single infectious agent. The European Regimen Accelerator for Tuberculosis (ERA4TB) is a public-private partnership of 30+ institutions with the objective to progress new anti-TB regimens into the clinic. Thus, robust and replicable results across independent laboratories are essential for reliable interpretation of treatment efficacy. A standardization workgroup unified in vitro protocols and data reporting templates. Time-kill assays provide essential input data for pharmacometric model-informed translation of single agents and regimens activity from in vitro to in vivo and the clinic. Five conditions were assessed by time-kill assays in six independent laboratories using four bacterial plating methods. Baseline bacterial burden varied between laboratories but variability was limited in net drug effect, confirming 2.5 μL equally robust as 100 μL plating. This exercise establishes the foundations of collaborative data generation, reporting, and integration within the overarching Antimicrobial Resistance Accelerator program.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Evaluation of critical parameters in the hollow-fibre system for tuberculosis: A case study of moxifloxacin

  • Aguilar-Ayala, Diana A.
  • Sanz-García, Fernando
  • Rabodoarivelo, Marie Sylvianne
  • Susanto, Budi O.
  • Bailo, Rebeca
  • Eveque-Mourroux, Maxime R.
  • Willand, Nicolas
  • Simonsson, Ulrika S. H.
  • Ramón-García, Santiago
  • Lucía, Ainhoa
AimsThe hollow‐fibre system for tuberculosis (HFS‐TB) is a preclinical model qualified by the European Medicines Agency to underpin the anti‐TB drug development process. It can mimic in vivo pharmacokinetic (PK)–pharmacodynamic (PD) attributes of selected antimicrobials, which could feed into in silico models to inform the design of clinical trials. However, historical data and published protocols are insufficient and omit key information to allow experiments to be reproducible. Therefore, in this work, we aim to optimize and standardize various HFS‐TB operational procedures.MethodsFirst, we characterized bacterial growth dynamics with different types of hollow‐fibre cartridges, Mycobacterium tuberculosis strains and media. Second, we mimicked a moxifloxacin PK profile within hollow‐fibre cartridges, in order to check drug–fibres compatibility. Lastly, we mimicked the moxifloxacin total plasma PK profile in human after once daily oral dose of 400 mg to assess PK–PD after different sampling methods, strains, cartridge size and bacterial adaptation periods before drug infusion into the system.ResultsWe found that final bacterial load inside the HFS‐TB was contingent on the studied variables. Besides, we demonstrated that drug–fibres compatibility tests are critical preliminary HFS‐TB assays, which need to be properly reported. Lastly, we uncovered that the sampling method and bacterial adaptation period before drug infusion significantly impact actual experimental conclusions.ConclusionOur data contribute to the necessary standardization of HFS‐TB experiments, draw attention to multiple aspects of this preclinical model that should be considered when reporting novel results and warn about critical parameters in the HFS‐TB currently overlooked.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Protocol to quantify bacterial burden in time-kill assays using colony-forming units and most probable number readouts for Mycobacterium tuberculosis

  • Rabodoarivelo, Marie Sylvianne
  • Hoffmann, Eik
  • Gaudin, Cyril
  • Aguilar-Ayala, Diana Angélica
  • Galizia, Jordana
  • Sonnenkalb, Lindsay
  • Dal Molin, Michael
  • Cioetto-Mazzabò, Laura
  • Degiacomi, Giulia
  • Recchia, Deborah
  • Rybniker, Jan
  • Manganelli, Riccardo
  • Pasca, Maria Rosalia
  • Ramón-García, Santiago
  • Lucía, Ainhoa
Here, we present a protocol to perform a time-kill assay (TKA) to quantify bacterial burden at multiple time points using colony-forming units and most probable number readouts simultaneously. We describe steps for preparing inoculum, experimental conditions, and sampling bacterial counts. We then detail procedures for quantification and analysis. TKAs provide longitudinal data reflecting the dynamics of the antibiotic effect over time against a planktonic culture and quantify the concentration-effect relationship.Here, we present a protocol to perform a time-kill assay (TKA) to quantify bacterial burden at multiple time points using colony-forming units and most probable number readouts simultaneously. We describe steps for preparing inoculum, experimental conditions, and sampling bacterial counts. We then detail procedures for quantification and analysis. TKAs provide longitudinal data reflecting the dynamics of the antibiotic effect over time against a planktonic culture and quantify the concentration-effect relationship.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

The ribosomal RNA synthesis ratio biomarker in Mycobacterium ulcerans for drug activity evaluation

  • Calvet-Seral, Juan
  • Sáez-López, Emma
  • López-Expósito, Patricio R.
  • Ferrer-Bazaga, Santiago
  • Vaquero, Juan José
  • Ramón-García, Santiago
  • Mendoza-Losana, Alfonso
Buruli ulcer (BU), a neglected tropical disease caused by Mycobacterium ulcerans (Mul), is treated with an 8-week regimen of rifampicin (RIF) and clarithromycin (CLA). Clinical trials are currently evaluating amoxicillin/clavulanate (AMX/CLV) co-administration to reduce treatment duration. However, conventional methods for assessing in vitro drug efficacy against Mul, like colony-forming units (CFUs), are slow and cumbersome. The ribosomal RNA synthesis ratio (RS-ratio) measures ribosome biogenesis and serves as a proxy of metabolic activity. While it is a promising predictive biomarker for treatment shortening in tuberculosis, its application in Mul remains unexplored. Here, we evaluated the RS-ratio for Mul drug activity assessment through RNA extractions from time-kill assays using RIF, CLA, and AMX/CLV, alone or in combinations. RIF + AMX/CLV-containing combinations produced a potent, rapid RS-ratio reduction, decreasing from a baseline of ≈2000 to ≈200 as early as day 3, and reaching their maximal inhibition (≈50–60) between days 7 and 10. Notably, this metabolic decline preceded the CFUs and luminescence drops observed in prior studies. Interestingly, the RS-ratio detected a metabolic recovery between days 14 and 28 (≈400), suggesting remaining bacterial viability, a phenomenon not observed by CFUs or luminescence. In summary, this is the first report using the RS-ratio to evaluate antibiotic activity against Mul. Our findings validate the RS-ratio as a molecular tool for assessing the sterilizing potential of new regimens to inform future research and clinical trial designs for the treatment of BU. Our results support the RIF + CLA + AMX/CLV regimen selection for BU treatment shortening in the BLMs4BU clinical trials (NCT05169554, PACTR202209521256638).
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

In vitro pharmacokinetics and pharmacodynamics of the diarylquinoline TBAJ-587 and its metabolites against Mycobacterium tuberculosis

  • Aguilar-Ayala, Diana Angelica
  • Rabodoarivelo, Marie Sylvianne
  • Eveque-Mourroux, Maxime R.
  • Leding, Albin A. M.
  • Sonnenkalb, Lindsay
  • Picó Marco, Ana
  • Willand, Nicolas
  • Serbina, Natalya
  • Simonsson, Ulrika S. H.
  • Lucía, Ainhoa
  • Ramón-García, Santiago
Introduction: The first-in-class diarylquinoline (DARQ) bedaquiline (BDQ) is in the medicines list for drug-resistant tuberculosis. TBAJ-587 is a next-generation DARQ with improved anti-Mycobacterium tuberculosis (Mtb) activity and reduced cardiac repolarization abnormalities. Methods: The in vitro efficacy of TBAJ-587 and its main metabolites (M2, M3 and M12) was analyzed under standard (ST) growth conditions and with cholesterol (CHO), or fatty acids (FA) as physiologically relevant alternative carbon sources. Minimal inhibitory concentration (MIC) assays and time-kill assays (TKA) linked to drug measurements in bacterial samples were performed to allow correlation of pharmacodynamics (PD) with actual in vitro pharmacokinetics (PK). Results: The most active compounds, TBAJ-587 and its M3 metabolite, exhibited broth media and concentration dependent efficacy showing a bactericidal effect at ≥5x MIC. Bacterial cultures treated with 1x MIC and 2x MIC of TBAJ-587 resumed growth after 28 days and displayed moderate increased MIC values compared to untreated conditions, which were linked to new variants of BDQ resistance mutations in the atpE, atpB, and Rv0678 genes. This study revealed that TBAJ-587 and its metabolites bind to polystyrene plastic-ware, the most commonly used material in antimicrobial research, being the effective unbound drug concentration dependent on the media composition. PKPD analyses determined that Mtb was killed with lower exposures of TBAJ-587 and M3 than expected in ST and FA broth, suggesting previously underestimated potency in these media. Discussion: Unlike commonly performed in in vitro PKPD studies that solely rely on nominal drug concentrations, our work precisely relates compound activity to actual effective concentrations that are measured over time directly in Mtb cultures, providing improved longitudinal data to feed in silico models for translational research.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

In vitro characterization of GSK2556286 in combination with bedaquiline and pretomanid against Mycobacterium tuberculosis

  • Rabodoarivelo, Marie Sylvianne
  • Galizia, Jordana
  • Recchia, Deborah
  • Stamilla, Alessandro
  • Dal Molin, Michael
  • Hoffmann, Eik
  • Gaudin, Cyril
  • Eveque, Maxime
  • Ndjogou, Dominique
  • Bailo, Rebeca
  • Leding, Albin A. M.
  • Simonsson, Ulrika S. H.
  • Sanz, Olalla
  • Jiménez, Elena
  • Bates, Robert H.
  • Degiacomi, Giulia
  • Lucía, Ainhoa
  • Willand, Nicolas
  • Baulard, Alain
  • Rybniker, Jan
  • Pasca, Maria Rosalia
  • Ramón-García, Santiago
GSK2556286 (GSK286) is a novel drug candidate with a cholesterol-dependent mode of action that has shown promising in vivo potential to improve tuberculosis treatment when combined with bedaquiline (B) and pretomanid (Pa). This study explored the in vitro activity of GSK286 alone and in combination with B and Pa, using extracellular and intracellular dose-response time-kill assays against different Mycobacterium tuberculosis (Mtb) strains. GSK286 demonstrated media-specific activity, inhibiting Mtb growth only in cholesterol- and propionate-containing media, with slight activity against both extracellular and intracellular Mtb. The Mtb strain overexpressing Mtb adenylyl cyclase Rv1625c exhibited higher susceptibility to GSK286, whereas the Rv1625c mutant was more resistant. This confirms GSK286’s mechanism of action linked to Rv1625c. GSK286 combined with BPa was bactericidal, although the main driver of this interaction was observed between GSK286 and B, with potency comparable to that of the triple BPa + GSK286 regimen, both extracellularly and intracellularly. These findings suggest that GSK286 may be a promising companion to B, with or without Pa, particularly under conditions with a sub-optimal B dose, where the GSK286 + B interaction was more clearly observed. These studies offer new insights into this drug combination to guide future research toward better tuberculosis treatments.